Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein

The CR3022 antibody, selected from a group of SARS-CoV monoclonal antibodies for its ability to cross-react with SARS-CoV-2, has been examined for its ability to bind to the ectodomain of the SARS-CoV-2 spike glycoprotein. Using cryo-electron microscopy we show that antibody binding requires rearran...

Descripción completa

Detalles Bibliográficos
Autores principales: Wrobel, Antoni G., Benton, Donald J., Hussain, Saira, Harvey, Ruth, Martin, Stephen R., Roustan, Chloë, Rosenthal, Peter B., Skehel, John J., Gamblin, Steven J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577971/
https://www.ncbi.nlm.nih.gov/pubmed/33087721
http://dx.doi.org/10.1038/s41467-020-19146-5
Descripción
Sumario:The CR3022 antibody, selected from a group of SARS-CoV monoclonal antibodies for its ability to cross-react with SARS-CoV-2, has been examined for its ability to bind to the ectodomain of the SARS-CoV-2 spike glycoprotein. Using cryo-electron microscopy we show that antibody binding requires rearrangements in the S1 domain that result in dissociation of the spike.

Ejemplares similares